Miguel Urpí-Ferreruela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Miguel Urpí-Ferreruela has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Begoña González-Suárez
Hospital Clínic de Barcelona ICMiD, N/A, Spain
5 shared publications - Gherzon Casanova
Hospital Clinic de Barcelona, Barcelona, Spain
5 shared publications - Angels Ginès
Hospital Clinic de Barcelona, Barcelona, Spain
2 shared publications - Antonio Giordano
Temple University
2 shared publications - Berta Caballol
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd) Barcelona Spain
2 shared publications - Gloria Fernández-Esparrach
Endoscopy Unit, Gastroenterology Department, ICMDM, Hospital Clinic, UB, C/Villarroel 170, 08036 Barcelona, Spain
2 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (11) , 3413-3421
Outcomes and Reclassification Patterns in Inflammatory Bowel Disease Unclassified: A Multicenter Study Matched With Ulcerative Colitis From Spanish ENEIDA Registry
Background and Aim: Around 10% of patients with inflammatory bowel disease do not fulfill the diagnostic criteria for Crohn's disease (CD) or ulcerative colitis (UC). These cases are labelled as inflammatory bowel disease unclassified (IBDU). The aim of the study was to compare therapeutic requirements in patients with IBDU and UC and to identify predictive factors of reclassification. Methods: This was a multicenter retrospective cohort study based on the ENEIDA registry. Patients diagnosed with IBDU or indeterminate colitis between January 2010 and December 2016 were included. All cases were matched by sex, age at diagnosis, and disease extent with at least two UC patients from the same hospital. The Kaplan–Meier method was performed to assess diagnostic changes during follow‐up. Fine–Gray competing‐risks regression analysis identified predictive factors of reclassification. Results: Two hundred and nine IBDU patients and 465 UC patients were included. After a median follow‐up of 90 months, no significant differences were observed in the use of immunomodulator (37.3% vs. 37%, p = 0.934) and advanced therapies (29.2% vs. 23.9%, p = 0.143) between IBDU and UC. No statistical differences were found in the surgical rates (5.7% vs. 4.7%, p = 0.579). Overall, 59 IBDU patients (28.2%) were reclassified (30 UC and 29 CD). Baseline extensive colitis was associated with a lower probability of subsequent reclassification to UC (SHR: 0.33; 95% CI: 0.12–0.91). No independent predictive factors for reclassification to CD were identified. Conclusions: Therapeutic management of IBDU and UC patients tended to be similar. Two‐thirds of patients remained classified as IBDU.
- 21 September 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (11) , 3413-3421
Open AccessOutcomes and Reclassification Patterns in Inflammatory Bowel Disease Unclassified: A Multicenter Study Matched With Ulcerative Colitis From Spanish ENEIDA Registry
Background and Aim: Around 10% of patients with inflammatory bowel disease do not fulfill the diagnostic criteria for Crohn's disease (CD) or ulcerative colitis (UC). These cases are labelled as inflammatory bowel disease unclassified (IBDU). The aim of the study was to compare therapeutic requirements in patients with IBDU and UC and to identify predictive factors of reclassification. Methods: This was a multicenter retrospective cohort study based on the ENEIDA registry. Patients diagnosed with IBDU or indeterminate colitis between January 2010 and December 2016 were included. All cases were matched by sex, age at diagnosis, and disease extent with at least two UC patients from the same hospital. The Kaplan–Meier method was performed to assess diagnostic changes during follow‐up. Fine–Gray competing‐risks regression analysis identified predictive factors of reclassification. Results: Two hundred and nine IBDU patients and 465 UC patients were included. After a median follow‐up of 90 months, no significant differences were observed in the use of immunomodulator (37.3% vs. 37%, p = 0.934) and advanced therapies (29.2% vs. 23.9%, p = 0.143) between IBDU and UC. No statistical differences were found in the surgical rates (5.7% vs. 4.7%, p = 0.579). Overall, 59 IBDU patients (28.2%) were reclassified (30 UC and 29 CD). Baseline extensive colitis was associated with a lower probability of subsequent reclassification to UC (SHR: 0.33; 95% CI: 0.12–0.91). No independent predictive factors for reclassification to CD were identified. Conclusions: Therapeutic management of IBDU and UC patients tended to be similar. Two‐thirds of patients remained classified as IBDU.
- Open Access
- 24 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1807
The Role of Gut Microbiota in Gastrointestinal Immune Homeostasis and Inflammation: Implications for Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), a heterogeneous group of recurring inflammatory conditions of the digestive system that encompass both ulcerative colitis (UC) and Crohn’s disease (CD), pose a significant public health challenge, currently lacking a definitive cure. The specific etiopathogenesis of IBD is not yet fully understood, but a multifactorial interplay of genetic and environmental factors is suspected. A growing body of evidence supports the involvement of intestinal dysbiosis in the development of IBD, including the effects of dysbiosis on the integrity of the intestinal epithelial barrier, modulation of the host immune system, alterations in the enteric nervous system, and the perpetuation of chronic inflammation. A comprehensive understanding of these mechanisms is important to define preventive measures, to develop new effective and lasting treatments, and to improve disease outcome. This review examines the complex tri-directional relationship between gut microbiota, mucosal immune system, and intestinal epithelium in IBD. In addition, nonpharmacological and behavioral strategies aimed at restoring a proper microbial–immune relationship will be suggested.
- 24 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1807
Open AccessThe Role of Gut Microbiota in Gastrointestinal Immune Homeostasis and Inflammation: Implications for Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), a heterogeneous group of recurring inflammatory conditions of the digestive system that encompass both ulcerative colitis (UC) and Crohn’s disease (CD), pose a significant public health challenge, currently lacking a definitive cure. The specific etiopathogenesis of IBD is not yet fully understood, but a multifactorial interplay of genetic and environmental factors is suspected. A growing body of evidence supports the involvement of intestinal dysbiosis in the development of IBD, including the effects of dysbiosis on the integrity of the intestinal epithelial barrier, modulation of the host immune system, alterations in the enteric nervous system, and the perpetuation of chronic inflammation. A comprehensive understanding of these mechanisms is important to define preventive measures, to develop new effective and lasting treatments, and to improve disease outcome. This review examines the complex tri-directional relationship between gut microbiota, mucosal immune system, and intestinal epithelium in IBD. In addition, nonpharmacological and behavioral strategies aimed at restoring a proper microbial–immune relationship will be suggested.
- 22 September 2023
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 99 (2) , 283-284
Endoscopic diagnosis of a neuroendocrine neoplasm inside a Meckel’s diverticulum: a capsule endoscopy finding
- 22 September 2023
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 99 (2) , 283-284
Endoscopic diagnosis of a neuroendocrine neoplasm inside a Meckel’s diverticulum: a capsule endoscopy finding
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S43-S44
Comparison Of An Artificial Intelligence Capsule Endoscopy System (Navicam) with the conventional Capsule Endoscopy (Pillcam Sb3) In The Study Of Small Bowel Pathology: Navipill Pilot Study
Aims Artificial intelligence can improve reading times and lesion detection rates in Small Bowel Capsule Endoscopy (SBCE).Compare the reading with artificial intelligence (AIR) of the Navicam Capsule with the conventional reading (CR) of PillcamR SB3 (gold standard). Methods Prospective clinical trial comparing AIR and CR (non-inferiority study). The 2 SBCE were administered to the same patient in randomized order with 60-minute intervals. AIR and CR were performed by two independent expert investigators. Diagnostic performance (percentage of lesions compatible with the indication for the test), diagnostic accuracy and reading times of the AIR compared to CR were evaluated. Results Twenty patients (median age 60 ± 10 years) were included. SBCE studies were complete with Navicam and Pillcam in 100% and 95% (p=1). The diagnostic yield by AIR and CR was 80% and 90% (p=0.5). The two readings agreed in 90% of the cases (Cohen's k 0.62). In the analysis per patient, the AIR presented sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy of 88%, 100%, 100%, 60%, and 90%, respectively. In the analysis per lesion, the AIR showed sensitivity, specificity, PPV, NPV, and diagnostic accuracy of 97%, 50%, 95%, 60%, and 93%, respectively. Mean reading time was 3.2 ±3.9 minutes with AIR and 27.5 ±9. 4 minutes with CR (p < 0.001). Conclusions AIR with NavicamR shows high agreement with CR with PillcamR. AI demonstrates high diagnostic yield and accuracy, with a significant reduction of reading times. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S43-S44
Comparison Of An Artificial Intelligence Capsule Endoscopy System (Navicam) with the conventional Capsule Endoscopy (Pillcam Sb3) In The Study Of Small Bowel Pathology: Navipill Pilot Study
Aims Artificial intelligence can improve reading times and lesion detection rates in Small Bowel Capsule Endoscopy (SBCE).Compare the reading with artificial intelligence (AIR) of the Navicam Capsule with the conventional reading (CR) of PillcamR SB3 (gold standard). Methods Prospective clinical trial comparing AIR and CR (non-inferiority study). The 2 SBCE were administered to the same patient in randomized order with 60-minute intervals. AIR and CR were performed by two independent expert investigators. Diagnostic performance (percentage of lesions compatible with the indication for the test), diagnostic accuracy and reading times of the AIR compared to CR were evaluated. Results Twenty patients (median age 60 ± 10 years) were included. SBCE studies were complete with Navicam and Pillcam in 100% and 95% (p=1). The diagnostic yield by AIR and CR was 80% and 90% (p=0.5). The two readings agreed in 90% of the cases (Cohen's k 0.62). In the analysis per patient, the AIR presented sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy of 88%, 100%, 100%, 60%, and 90%, respectively. In the analysis per lesion, the AIR showed sensitivity, specificity, PPV, NPV, and diagnostic accuracy of 97%, 50%, 95%, 60%, and 93%, respectively. Mean reading time was 3.2 ±3.9 minutes with AIR and 27.5 ±9. 4 minutes with CR (p < 0.001). Conclusions AIR with NavicamR shows high agreement with CR with PillcamR. AI demonstrates high diagnostic yield and accuracy, with a significant reduction of reading times. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S254
Prospective and comparative observational study between Single-Balloon Enteroscopy and Motorized Spiral Enteroscopy
Aims Motorized Spiral Enteroscopy (MSE) emerged as a technique with higher insertion depth and shorter exploration time. However, comparative studies with previous techniques are scarce. We aimed to compare Single-Balloon Enteroscopy (SBE) and MSE efficacy and safety. Methods Prospective and comparative observational study conducted on patients undergoing SBE or MSE in a tertiary hospital from December 2019 to July 2022. Demographic characteristics, procedure indication, small bowel exploration time (SBET), technical success, depth of maximum insertion (DMI), diagnostic, therapeutic, interventional yield and adverse events (AE), were collected. Data was analyzed using IBM SPSS Statistics 28.0 [1] [2] [3] [4] [5]. Results A total of 323 enteroscopies (152 SBE and 171 MSE) were performed in 267 patients. Suspected small bowel bleeding was the most frequent indication (72.2%). Insertion was anterograde in 213 cases (123 SBE/ 90 MSE) and retrograde in 110 cases (29 SBE/ 81 MSE). Technical success was 98% with SBE and 92.35% with EMS (p=0.019), performing complete enteroscopies only with MSE (0% vs 10.4%, p<0.001). For the anterograde route, SBE showed significantly lower DMI than MSE (229.80+/-86.32cm vs 430.55+/-211.98cm, p<0.001). No statistical differences were found regarding SBET (39min vs 34.22min, pNS). The diagnostic yield was 72.3% and 65% (pNS), the therapeutic yield was 63.8% and 40.9% (p<0.001), and interventional yield was 86.8% and 68.4% for SBE and MSE, respectively (p<0.001). No differences were found regarding AE rate (4.6% vs 9.3%, pNS). Conclusions Both techniques, SBE and MSE, are effective and safe. SBE has better performance in the therapeutic and interventional yield. MSE allows a higher DMI for the anterograde route. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S254
Prospective and comparative observational study between Single-Balloon Enteroscopy and Motorized Spiral Enteroscopy
Aims Motorized Spiral Enteroscopy (MSE) emerged as a technique with higher insertion depth and shorter exploration time. However, comparative studies with previous techniques are scarce. We aimed to compare Single-Balloon Enteroscopy (SBE) and MSE efficacy and safety. Methods Prospective and comparative observational study conducted on patients undergoing SBE or MSE in a tertiary hospital from December 2019 to July 2022. Demographic characteristics, procedure indication, small bowel exploration time (SBET), technical success, depth of maximum insertion (DMI), diagnostic, therapeutic, interventional yield and adverse events (AE), were collected. Data was analyzed using IBM SPSS Statistics 28.0 [1] [2] [3] [4] [5]. Results A total of 323 enteroscopies (152 SBE and 171 MSE) were performed in 267 patients. Suspected small bowel bleeding was the most frequent indication (72.2%). Insertion was anterograde in 213 cases (123 SBE/ 90 MSE) and retrograde in 110 cases (29 SBE/ 81 MSE). Technical success was 98% with SBE and 92.35% with EMS (p=0.019), performing complete enteroscopies only with MSE (0% vs 10.4%, p<0.001). For the anterograde route, SBE showed significantly lower DMI than MSE (229.80+/-86.32cm vs 430.55+/-211.98cm, p<0.001). No statistical differences were found regarding SBET (39min vs 34.22min, pNS). The diagnostic yield was 72.3% and 65% (pNS), the therapeutic yield was 63.8% and 40.9% (p<0.001), and interventional yield was 86.8% and 68.4% for SBE and MSE, respectively (p<0.001). No differences were found regarding AE rate (4.6% vs 9.3%, pNS). Conclusions Both techniques, SBE and MSE, are effective and safe. SBE has better performance in the therapeutic and interventional yield. MSE allows a higher DMI for the anterograde route. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 15 September 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (9) , 2226
Fecal Calprotectin for Small Bowel Crohn’s Disease: Is It a Cutoff Issue?
(1) Background: Fecal calprotectin (FC) correlates well with colonic inflammatory activity of Crohn’s disease (CD); data about relation of FC and small bowel (SB) lesions are still contradictory. The main aim was to analyze the relationship between FC levels and SB inflammatory activity in patients with established or suspected Crohn’s disease, assessed by small bowel capsule endoscopy (SBCE) or magnetic resonance enterography (MRE). (2) Methods: Two cohorts of patients were included: 1. Prospective data were collected from patients with established or suspected CD who underwent SBCE and FC (Cohort A); 2. A retrospective cohort of patients who underwent MRE and FC determination (Cohort B). Different cutoffs for FC were tested in both cohorts. (3) Results: 83 patients were included and 66 were finally analyzed. A total of 69.6% had SB lesions seen by SBCE (n = 25) or MRE (n = 21). FC mean levels were 605.74 + 607.07 μg/g (IQ range: 99.00–878.75), being significantly higher in patients with SB lesions compared to patients without lesions (735.91 + 639.70 μg/g (IQ range: 107.75–1366.25) vs. 306.35 + 395.26 μg/g (IQ range: 78.25–411.0), p < 0.005). For cohort A, 25 out of 35 patients had SB lesions and a significant correlation between Lewis Score and FC levels was achieved (R2: 0.34; p = 0.04). FC sensitivity (S), specificity (E), positive predictive value (PPV), and negative predictive values (NPV) for predicting SB lesions were 80%, 50%, 80%, and 50%, respectively, for FC > 100 µg/g. For cohort B, inflammatory SB activity, measured by MaRIA score, was detected in 21 out of 31 patients (67.7%). Patients with positive findings in MRE had significantly higher values of FC than those with no lesions (944.9 + 672.1 µg/g vs. 221 + 212.2 µg/g, p < 0.05). S, E, PPV, and NPV of FC were 89%, 50%, 77.2%, and 71.4% for FC levels > 100 µg/g. The higher sensitivity and specificity of the FC levels for the detection of SB lesions with SBCE and MRE was obtained for an FC cutoff >265 μg/g and >430 μg/g, respectively. (4) Conclusions: FC has a good correlation with the presence of SB lesions, assessed by SBCE and MRE, in patients with established or suspected Crohn’s disease. However, the ideal cutoff is here proven to be higher than previously reported. Multicenter and large prospective studies are needed in order to establish definitive FC cutoff levels.
- 15 September 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (9) , 2226
Open AccessFecal Calprotectin for Small Bowel Crohn’s Disease: Is It a Cutoff Issue?
(1) Background: Fecal calprotectin (FC) correlates well with colonic inflammatory activity of Crohn’s disease (CD); data about relation of FC and small bowel (SB) lesions are still contradictory. The main aim was to analyze the relationship between FC levels and SB inflammatory activity in patients with established or suspected Crohn’s disease, assessed by small bowel capsule endoscopy (SBCE) or magnetic resonance enterography (MRE). (2) Methods: Two cohorts of patients were included: 1. Prospective data were collected from patients with established or suspected CD who underwent SBCE and FC (Cohort A); 2. A retrospective cohort of patients who underwent MRE and FC determination (Cohort B). Different cutoffs for FC were tested in both cohorts. (3) Results: 83 patients were included and 66 were finally analyzed. A total of 69.6% had SB lesions seen by SBCE (n = 25) or MRE (n = 21). FC mean levels were 605.74 + 607.07 μg/g (IQ range: 99.00–878.75), being significantly higher in patients with SB lesions compared to patients without lesions (735.91 + 639.70 μg/g (IQ range: 107.75–1366.25) vs. 306.35 + 395.26 μg/g (IQ range: 78.25–411.0), p < 0.005). For cohort A, 25 out of 35 patients had SB lesions and a significant correlation between Lewis Score and FC levels was achieved (R2: 0.34; p = 0.04). FC sensitivity (S), specificity (E), positive predictive value (PPV), and negative predictive values (NPV) for predicting SB lesions were 80%, 50%, 80%, and 50%, respectively, for FC > 100 µg/g. For cohort B, inflammatory SB activity, measured by MaRIA score, was detected in 21 out of 31 patients (67.7%). Patients with positive findings in MRE had significantly higher values of FC than those with no lesions (944.9 + 672.1 µg/g vs. 221 + 212.2 µg/g, p < 0.05). S, E, PPV, and NPV of FC were 89%, 50%, 77.2%, and 71.4% for FC levels > 100 µg/g. The higher sensitivity and specificity of the FC levels for the detection of SB lesions with SBCE and MRE was obtained for an FC cutoff >265 μg/g and >430 μg/g, respectively. (4) Conclusions: FC has a good correlation with the presence of SB lesions, assessed by SBCE and MRE, in patients with established or suspected Crohn’s disease. However, the ideal cutoff is here proven to be higher than previously reported. Multicenter and large prospective studies are needed in order to establish definitive FC cutoff levels.